Publications
663 results found
Camidge DR, Sugawara S, Kondo M, et al., 2023, Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced <i>ALK</i> plus NSCLC in the ALTA-1L and J-ALTA studies, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Homicsko K, Zygoura G, Tissot S, et al., 2023, Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Sirohi B, Davis S, Anu R, et al., 2023, Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Girard N, Aix SP, Cedres S, et al., 2023, Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial, ESMO OPEN, Vol: 8
- Author Web Link
- Cite
- Citations: 1
Wu MY, Shepherd STC, Fendler A, et al., 2023, Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer, CANCER CELL, Vol: 41, Pages: 821-823, ISSN: 1535-6108
Reck M, Popat S, Grohe C, et al., 2023, Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives, LUNG CANCER, Vol: 179, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 2
Ng K, Boumelha J, Enfield KSS, et al., 2023, Antibodies against endogenous retroviruses promote lung cancer immunotherapy, NATURE, Vol: 616, Pages: 563-+, ISSN: 0028-0836
- Author Web Link
- Cite
- Citations: 11
O'Sullivan H, MacMahon S, Proszek P, et al., 2023, The spectrum of MET exon 14 skipping alterations in a UK population, Publisher: ELSEVIER IRELAND LTD, Pages: S32-S33, ISSN: 0169-5002
King S, Stergiopoulos S, Curtis M, et al., 2023, A population-adjusted indirect treatment comparison of efficacy and safety of aumolertinib vs osimertinib in EGFR-mutated non-small cell lung cancer, Publisher: ELSEVIER IRELAND LTD, Pages: S36-S37, ISSN: 0169-5002
Zhang YZ, Sherlock S, MacMahon S, et al., 2023, Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting, Publisher: ELSEVIER IRELAND LTD, Pages: S1-S2, ISSN: 0169-5002
Milner-Watts C, O'Sullivan H, Stewart J, et al., 2023, Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer, Publisher: ELSEVIER IRELAND LTD, Pages: S31-S32, ISSN: 0169-5002
Popat S, Ramalingam S, Zhou C, et al., 2023, Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study, Publisher: ELSEVIER IRELAND LTD, Pages: S35-S35, ISSN: 0169-5002
Mulla K, Farag S, Moore B, et al., 2023, Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment, Diabetic Medicine, Vol: 40, Pages: 1-10, ISSN: 0742-3071
AimsWe systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia,MethodsRetrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.ResultsOverall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new-onset hyperglycaemia (without pre-existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.ConclusionsHyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.
Farag S, Mulla K, Moore B, et al., 2023, Diabetes and metformin use negatively impacts survival in lung cancer patients receiving immunotherapy, Publisher: WILEY, ISSN: 0742-3071
Kroeze SGC, Pavic M, Stellamans K, et al., 2023, Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium, LANCET ONCOLOGY, Vol: 24, Pages: e121-e132, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 11
Camidge DR, Kim HR, Ahn MJ, et al., 2023, Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L, Publisher: ELSEVIER SCIENCE INC, Pages: E27-E27, ISSN: 1556-0864
Popat S, Ahn M-J, Ekman S, et al., 2023, Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Jan, 10.1007/s11523-022-00941-7, 2023), TARGETED ONCOLOGY, Vol: 18, Pages: 311-311, ISSN: 1776-2596
Cerone MA, Mills TC, Sharpe R, et al., 2023, The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (JAN, 10.1038/s41416-023-02160-x, 2023), BRITISH JOURNAL OF CANCER, Vol: 128, Pages: 399-399, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 1
Cerone MA, Mills TC, Sharpe R, et al., 2023, The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care, BRITISH JOURNAL OF CANCER, Vol: 128, Pages: 161-164, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 1
Garcia Campelo MR, Zhou C, Ramalingam SS, et al., 2023, Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort, JOURNAL OF CLINICAL MEDICINE, Vol: 12
- Author Web Link
- Cite
- Citations: 2
Popat S, Ahn M-J, Ekman S, et al., 2023, Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies, TARGETED ONCOLOGY, Vol: 18, Pages: 9-24, ISSN: 1776-2596
- Author Web Link
- Cite
- Citations: 1
Paz-Ares LG, Ciuleanu T-E, Pluzanski A, et al., 2023, Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817, JOURNAL OF THORACIC ONCOLOGY, Vol: 18, Pages: 79-92, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 5
O'Sullivan HM, Feber A, Popat S, 2023, Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions, ONCOTARGETS AND THERAPY, Vol: 16, Pages: 249-259, ISSN: 1178-6930
- Author Web Link
- Cite
- Citations: 1
Mirza M, Shrivastava A, Matthews C, et al., 2023, Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report., Front Oncol, Vol: 13, ISSN: 2234-943X
INTRODUCTION: Osimertinib is recommended by major guidelines for use in the adjuvant setting in patients with EGFR mutation-positive NSCLC following the significant improvement in disease-free survival observed in the Phase III ADAURA trials. Due to limited real-world data in the adjuvant setting, little guidance exists on how to approach potential recurrences either during or after the completion of the treatment. This study aimed to reach a broad consensus on key treatment decision criteria in the events of recurrence. METHODS: To reach a broad consensus, a modified Delphi panel study was conducted consisting of two rounds of surveys, followed by two consensus meetings and a final offline review of key statements. An international panel of experts in the field of NSCLC (n=12) was used to provide clinical insights regarding patient management at various stages of NSCLC disease including patient monitoring, diagnostics, and treatment approach for specific recurrence scenarios. This study tested recurrences occurring 1) within or outside the central nervous system (CNS), 2) during or after the adjuvant-osimertinib regimen in NSCLC disease which is 3) amenable or not amenable to local consolidative therapy. RESULTS: Panellists agreed on various aspects of patient monitoring and diagnostics including the use of standard techniques (e.g., CT, MRI) and tumour biomarker assessment using tissue and liquid biopsies. Consensus was reached on 6 statements describing treatment considerations for the specific NSCLC recurrence scenarios. Panellists agreed on the value of osimertinib as a monotherapy or as part of the overall treatment strategy within the probed recurrence scenarios and acknowledged that more clinical evidence is required before precise recommendations for specific patient populations can be made. DISCUSSION: This study provides a qualitative expert opinion framework for clinicians to consider within their treatment decision-making when faced with recurrence duri
Ahn MJ, Kim HR, Yang JCH, et al., 2022, Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive<i> ALK plus </i> Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study, CLINICAL LUNG CANCER, Vol: 23, Pages: 720-730, ISSN: 1525-7304
- Author Web Link
- Cite
- Citations: 2
Kent S, Gupta A, Duffield S, et al., 2022, BIAS ADJUSTING FOR UNMEASURED CONFOUNDERS IN SYNTHETIC CONTROL ANALYSIS (SCA) ESTIMATES OF IMMUNOTHERAPY EFFECTIVENESS IN ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): AN OUTPUT FROM THE Q-BASEL STUDY, Publisher: ELSEVIER SCIENCE INC, Pages: S374-S374, ISSN: 1098-3015
Meunier A, Longworth L, Popat S, et al., 2022, DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER TREATMENTS FROM AN NHS ENGLAND PERSPECTIVE, Publisher: ELSEVIER SCIENCE INC, Pages: S339-S339, ISSN: 1098-3015
Popat S, Fidyk C, Patel R, 2022, Demographic Analysis of Cancer Patients Who Voluntarily Used a Digital Health Tool to Self-Report Medications, Symptoms and Well-Being, Publisher: ELSEVIER SCIENCE INC, Pages: S396-S396, ISSN: 1098-3015
Stergiopoulos S, King S, Curtis M, et al., 2022, INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC), Publisher: ELSEVIER SCIENCE INC, Pages: S42-S42, ISSN: 1098-3015
Chouaid C, Girard N, Kron A, et al., 2022, AMIVANTAMAB VERSUS REAL-WORLD CLINICAL PRACTICE IN EUROPE AND THE US FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS, Publisher: ELSEVIER SCIENCE INC, Pages: S32-S32, ISSN: 1098-3015
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.